ArticleFrontiers in endocrinology2025
Predictive value of serum uric acid to high-density lipoprotein cholesterol ratio for MAFLD in non-obese type 2 diabetes patients based on nomogram.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: In non-obese type 2 diabetes (T2DM) patients, the incidence of metabolic dysfunction associated fatty liver disease (MAFLD) is very insidious and easily overlooked in clinical examinations. The aim of our article is to explore whether the serum uric acid to High-density lipoprotein cholesterol (HDL-C) ratio (UHR) can be used for independent assessment of the risk of MAFLD in non-obese T2DM patients. Methods: 1622 T2DM patients were analyzed, and 506 non-obese patients were ultimately included in the study. Routine clinical and laboratory date were collected. In the non-obese T2DM population, the stability of UHR in predicting MAFLD was evaluated through subgroup analysis, and compared UHR with other indicators. Finally, we used logistic regression and established a nomogram model to assess the diagnostic efficacy of UHR for MAFLD. To evaluate the nomogram's predictive performance, we employed a suite of techniques including receiver operating characteristic (ROC) analysis, calibration curve assessment, and decision curve analysis (DCA). Results: As UHR levels increased, the prevalence of MAFLD gradually increased in non-obese T2DM patients. Logistic regression indicated that UHR was associated with MAFLD in non-obese T2DM participants. We constructed a nomogram model using UHR, 2 hour postprandial glucose (2h-PG), 2 hour C-Peptide (2hC-P), body mass index (BMI), triglycerides (TG), serum creatinine (CRE), and C-reactive protein (CRP) as predictive factors to estimate the probability of developing MAFLD in non-obese T2DM subjects. The clinical utility of the model was supported by its strong performance on both the calibration curve and DCA. Conclusions: In non-obese T2DM patients, the morbidity rate of MAFLD was significantly higher in high level UHR subjects than that in low level UHR subjects. in non-obese T2DM patients, the nomogram model constructed based on UHR, BMI, 2h-PG, 2hC-P, TG, CRE, and CRP had good predictive ability for the risk of MAFLD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.